Remove Immune Response Remove Licensing Remove Production
article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

He showed that these synthetic CAR T cells could launch an immune response when they encountered the corresponding tumor protein, called CD19. The next step was to adapt cell culture techniques to enable the production of effective CAR T cells for infusion to patients.

article thumbnail

GSK Licenses Shigella Vaccine Candidate to Bharat Biotech

The Pharma Data

GSK Licenses Shigella Vaccine Candidate to Bharat Biotech in Push for Global Health Equity GSK today announced a significant step forward in the battle against Shigella a leading cause of diarrhoeal disease and death in children under five by licensing its Shigella vaccine candidate, altSonflex1-2-3 , to Bharat Biotech International Limited (BBIL).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA takes major step to ease access to CAR-T therapy

BioPharma Drive: Drug Pricing

Published June 27, 2025 Ned Pagliarulo Lead Editor post share post print email license Bristol Myers Squibb sells two CAR-T cell therapies for cancer. For some people with leukemia, lymphoma or multiple myeloma, they can prompt powerful responses and even long-lasting remission.

article thumbnail

Sanofi to acquire vaccine biotech in billion-dollar deal

BioPharma Drive: Drug Pricing

Published July 22, 2025 • Updated 2 hours ago Delilah Alvarado Staff Reporter post share post print email license A sign bearing Sanofi's logo sits outside the company's U.S. An antibody drug, Beyfortus , that Sanofi developed with partner AstraZeneca has become a blockbuster product for preventing RSV disease in infants.

article thumbnail

Unlocking the power of stem cell therapy

Drug Target Review

Additionally, ADSCs possess immunomodulatory properties, enabling them to modulate immune responses and promote tissue healing. Moreover, their immunomodulatory properties make them valuable assets in managing autoimmune diseases by suppressing aberrant immune responses.

article thumbnail

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

The Pharma Data

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. ImaginAb’s products have the potential to improve patient care and lower healthcare costs.

article thumbnail

4-1BB and the critical importance of local control

SugarCone Biotech

Targeting 4-1BB remained of interest to the immuno-oncology field as cell culture experiments and tumor models in mice suggested that robust anti-tumor immune responses could be triggered by anti-4-1BB antibody therapies. This is the T cell type most closely associated with anti-tumor immune responses. 2023.09.011 ).